Holen Sie sich die Stockscreener-App
74.21
0.60%
0.44
Schlusskurs vom Vortag:
$73.77
Offen:
$73.93
24-Stunden-Volumen:
573.14K
Relative Volume:
1.03
Marktkapitalisierung:
$3.57B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$123.81M
KGV:
30.79
EPS:
2.41
Netto-Cashflow:
$20.35M
1W Leistung:
-0.55%
1M Leistung:
+4.40%
6M Leistung:
+1.17%
1J Leistung:
-17.77%
1-Tages-Spanne:
$73.28
$75.44
1-Wochen-Bereich:
$72.06
$75.44
52-Wochen-Spanne:
$55.30
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
74.21 | 3.58B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
What analysts say about Haemonetics Corporation stockAccelerated profit realization - Autocar Professional
What drives Haemonetics Corporation stock priceTriple-digit return opportunities - jammulinksnews.com
Haemonetics Corporation Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
Why Haemonetics Corporation stock attracts strong analyst attentionFree Expert Investment Advice - Newser
Is Haemonetics Corporation a good long term investmentHigh-margin investment plays - jammulinksnews.com
Nisa Investment Advisors LLC Has $50,000 Position in Haemonetics Corporation (NYSE:HAE) - Defense World
Is Haemonetics Corporation stock a growth or value playMulti Bagger Alerts - Newser
What makes Haemonetics Corporation stock price move sharplyBig Return Stock Tips - Newser
How Haemonetics Corporation stock performs during market volatilityHigh Win Rate Stock Ideas - Newser
Platelet Aggregation Devices Market Set to Witness Significant - openPR.com
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know - Yahoo Finance
Haemonetics Announces Q1 FY26 Earnings Release and Conference Call - AInvest
Haemonetics Shares Rise After Upgrade From Citigroup - MarketScreener
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes - Investing.com
5 Must-Read Analyst Questions From Haemonetics’s Q1 Earnings Call - Yahoo Finance
Analyst Baird Initiates Coverage on Haemonetics (HAE) with Outperform Rating | HAE Stock News - GuruFocus
Vivasure submits PMA for vascular closure system to FDA - Yahoo Home
Private cloud, AI compute markets continue to gain momentum - SiliconANGLE
Kalkine: Haemonetics (NYSE:HAE) Reflects Unique Sector Metrics in the russell 1000 - Kalkine Media
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Blood Platelets Market Deep Research Report with Forecast - openPR.com
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com
Transcript : Haemonetics Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Zacks Research Decreases Earnings Estimates for Haemonetics - Defense World
Q3 EPS Estimates for Haemonetics Decreased by Zacks Research - Defense World
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 36%? - Yahoo Finance
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Haemonetics (HAE) – Investment Analysts’ Recent Ratings Updates - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
HAEMONETICS CORP SEC 10-K Report - TradingView
JMP maintains Haemonetics stock $100 target post-results By Investing.com - Investing.com Canada
What 4 Analyst Ratings Have To Say About Haemonetics - Benzinga
Haemonetics (HAE) Stock Rating and Price Target Reaffirmed by JMP Securities | HAE Stock News - GuruFocus
JMP maintains Haemonetics stock $100 target post-results - Investing.com
Haemonetics Co. (NYSE:HAE) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Haemonetics Corporation (NYSE:HAE) Q4 2025 Earnings Call Transcript - Insider Monkey
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up - Yahoo Finance
Haemonetics’ (HAE) “Strong-Buy” Rating Reiterated at Raymond James - Defense World
Haemonetics Corporation Just Beat EPS By 8.7%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Haemonetics Full Year 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings - Yahoo Finance
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):